PharmEnable

PharmEnable, a Cambridge, UK-based biopharmaceutical company, operates at the intersection of artificial intelligence and medicinal chemistry to develop the next generation of small-molecule drugs. Spun out from the University of Cambridge in 2016, the company was co-founded by CEO Dr. Hannah Sore, a medicinal chemist with a background in both academia and business consulting, and COO Dr. Natalia Mateu, an organic and medicinal chemist. Their shared vision, conceived while working together at the university, was to tackle chemically challenging disease targets that are inaccessible to conventional drug discovery methods.

The core of PharmEnable's operation is its proprietary AI-powered platform, chemSEEK. This technology maps and explores vast, untapped areas of the chemical universe to design novel, three-dimensional small molecules. The platform's objective is to create orally available drugs that exhibit the high specificity and selectivity typically associated with biologic therapies, but with the added benefits of small molecules, such as improved distribution and lower manufacturing costs. The platform integrates advanced computational tools with the practical expertise of medicinal chemists to increase the probability of discovering effective drug candidates with fewer side effects.

PharmEnable's business model is dual-pronged. The company develops its own pipeline of wholly-owned therapeutics, with an initial focus on oncology and neurology, addressing challenges like tumor penetration and drug resistance. Concurrently, it engages in co-discovery partnerships with other pharmaceutical and biotech companies. Notable collaborations include partnerships with Sosei Heptares and Denali Therapeutics to discover new treatments for neurological diseases. The company is financed through a combination of service-based revenues and significant venture capital investment. Key funding milestones include a £1.8 million seed round in 2020 and a $7.5 million Pre-Series A round in 2023, led by MP Healthcare Venture Management, which has enabled the expansion of its R&D efforts and project portfolio.

Keywords: small-molecule therapeutics, AI drug discovery, medicinal chemistry, oncology, neurology, challenging drug targets, chemSEEK platform, Cambridge biotech, drug discovery partnerships, biologics specificity, computational chemistry, 3D molecules, undruggable targets, pre-clinical therapeutics, pharmaceutical collaboration, neurodegenerative disease, cancer treatment, chemical space exploration, structure-based drug design, G protein-coupled receptor